Source: Virtual Congress 2021 – Treatments for airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Schouten (Leiden, Netherlands), M. Kasteleyn (Leiden, Netherlands), R. Bals (Homburg/Saar, Germany), A. Turner (Birmingham, United Kingdom), I. Ferrarotti (Pavia, Italy), A. Corsico (Pavia, Italy), B. Lara Gallego (Coventry, United Kingdom), M. Miravitlles (Barcelona, Spain), R. Stockley (Birmingham, United Kingdom), J. Stolk (Leiden, Netherlands). Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients. 1833

Member's Comments

No comment yet.

Related content which might interest you: Long-term effect of a1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database Source: ERJ Open Res, 7 (3) 00194-2021; 10.1183/23120541.00194-2021 Year: 2021 Annual FEV1% variation before and after augmentation therapy in severe alpha-1-antitrypsin deficiency Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough Source: Eur Respir J 2016; 47: 35-38 Year: 2016 FVC decline in patients with SSc-ILD by use of anti-acid therapy Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Reducing the decline of FEV1 after a 4-year therapy with montelukast in patients with bronchial asthma Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008 Prevalence of alpha1-antitrypsin deficiency and its influence on lung function decline in patients with severe asthma Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Early ICS treatment in subjects with a rapid decline in lung function Source: Eur Respir J 2001; 18: Suppl. 33, 348s Year: 2001 Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017 Year: 2017 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Long-term effect of sildenafil on exercise capacity in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 608s Year: 2007 The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients? Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients Source: Eur Respir J, 51 (4) 1702258; 10.1183/13993003.02258-2017 Year: 2018 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy Source: Eur Respir Rev 2015; 24: 46-51 Year: 2015 Early health status improvements decline after LVRS despite persistent reduction in lung volume Source: Eur Respir J 2002; 20: Suppl. 38, 607s Year: 2002